Cisiv, established in 1995 and headquartered in the United Kingdom, offers a global integrated digital platform focused on non-interventional research, registries, and Expanded Access Programs. Operating at the intersection of Health Care, Information Technology, and Pharmaceutical industries, Cisiv caters to Pharmaceutical and Medical Device companies by facilitating real-world data collection and management.
Their proprietary platform, Baseline Plus, provides an end-to-end solution featuring comprehensive data collection and analytics, aiming to reduce data management costs by 60%. The platform's configurability and flexibility accommodate various research designs, from site-based to hybrid models, with an extensive array of functionalities including EDC, eConsent, and more. Impressively, 90% of the top global pharmaceutical companies employ Cisiv’s solutions, with over 200 projects supported.
The company's most recent funding was a Seed investment from Gresham House on 01 March 2019, indicating sustained investor interest and confidence in their scalable technology and market position.